| Previous Close | 50.400 |
| Open | 50.320 |
| Bid | 50.000 x 700 |
| Ask | 50.010 x 600 |
| Day's Range | 49.910 - 50.360 |
| 52 Week Range | 37.380 - 51.130 |
| Volume | 4,789,704 |
| Avg. Volume | 6,381,026 |
| Market Cap | 86.82B |
| Beta | 1.54 |
| PE Ratio (TTM) | 52.07 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.06 (2.09%) |
| Ex-Dividend Date | 2017-07-12 |
| 1y Target Est | N/A |
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
- Market Realist•yesterday
Analysts Raise Recommendations on Abbott Stock after 2Q17
Based on the recommendations of 19 brokerage firms in a Reuters survey, 68.0% rated Abbott Laboratories a “buy,” and 32.0% rated it a “hold.”
- Market Realist•yesterday
Abbott Laboratories’ Updated Guidance for 2017
In 3Q17, the company's operational sales growth is expected to be in the mid-single digits. Adjusted EPS is expected to be $0.64–$0.66.
